financetom
Business
financetom
/
Business
/
Snowflake shares surge on rosy forecast, AI deal with Anthropic
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Snowflake shares surge on rosy forecast, AI deal with Anthropic
Nov 21, 2024 6:52 AM

(Reuters) -Snowflake's shares surged more than 28% on Thursday after the data analytics provider raised its annual product revenue forecast, signaling growing demand for cloud-based data storage and analytics.

The company, whose shares have fallen 35% this year, is on track for its best day since going public in 2020.

Its value is set to increase by over $12 billion to a market cap of $43.3 billion if gains hold.

The Bozeman, Montana-based company's results come months after Sridhar Ramaswamy took over as CEO, having previously spearheaded Snowflake's AI strategy as SVP of AI, and analysts have been since watching how the firm's AI efforts are progressing under the new leadership.

Snowflake announced a partnership with Anthropic on Wednesday, which will allow its customers to enhance their AI applications using Anthropic's large language models on Snowflake's cloud-based data platforms.

The multi-year deal will also allow Snowflake's AI agents to analyze data and generate visualizations, among other functions, the company said.

The company expects product revenue of $3.43 billion for 2025, compared with its previous forecast of $3.36 billion.

"It does not sound like the macro is getting dramatically better, but the better sales execution and new product momentum are helping Snowflake to deliver these results," Barclays analysts wrote in a note.

At least 20 analysts hiked PT for the stock, while at least three upgraded their ratings on the stock. The median view stood at $185, representing an upside of 43.3%.

The company's shares were trading 147.32 times their 12-month forward profit expectations, compared with 67.01 for Datadog and MongoDB's 91.04.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved